<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SSD CREAM  - silver sulfadiazine cream </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>SSD™ (1% Silver Sulfadiazine Cream)SSD AF™ (1% Silver
      Sulfadiazine Cream)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"></p>
<p>SSD™ (1% Silver Sulfadiazine Cream) and SSD AF™ (1%
Silver Sulfadiazine Cream), 1% are topical antibacterial preparations which
have as their active antimicrobial ingredient silver sulfadiazine. The active
moiety is contained within an opaque, white, water miscible cream base.<br><br>
Each 1000 grams of SSD/SSD AF Cream contains 10 grams of silver sulfadiazine.<br><br><span class="Bold">Inactive Ingrediants: </span>cetyl alcohol (SSD
Cream only), isopropyl myristate, polyoxyl 40 stearate, propylene glycol,
purified water, stearyl alcohol, sodium hydroxide, sorbitan monooleate, white
petrolatum; with 0.3% methyl paraben, as a preservative.<br><br> Silver
sulfadiazine has an emprical formula of
C<span class="Sub">10</span>H<span class="Sub">9</span>AgN<span class="Sub">4</span>O<span class="Sub">2</span>S, molecular weight
of 357.14 and structural formula as shown:</p>
<p><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cecc0b75-fccf-418d-923a-2a5869c1d043&amp;name=MM1.jpg"></p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<p>Silver sulfadiazine has broad antimicrobial activity.  It is
bactericidal for many gram-negative and gram-positive bacteria as well as being
effective against yeast.  Results from <span class="Italics">in
vitro</span> testing are listed below.  Sufficient data have been obtained
to demonstrate that silver sulfadiazine will inhibit bacteria that are
resistant to other antimicrobial agents and that the compound is superior to
sulfadiazine.  Studies utilizing radioactive micronized silver sulfadiazine,
electron microscopy, and biochemical techniques have revealed that the
mechanism of action of silver sulfadiazine on bacteria differs from silver
nitrate and sodium sulfadiazine.  Silver sulfadiazine acts only on the cell
wall to produce its bactericidal effect.</p>
<p>Results of <span class="Italics">In Vitro</span> Testing With
Silver Sulfadiazine Cream, 1% Concentration of Silver Sulfadiazine <br>Number of
Sensitive <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span> / Total Number of <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span> Tested<br><br></p>
<p>Genus and Species                  50 micrograms/mL      100
micrograms/mL</p>
<p>Pseudomonas Aeruginosa            130/130                     130/130</p>
<p>Xanthomonas (Pseudomonas)</p>
<p>    Maltophilia                                 7/7                    
        7/7</p>
<p>Enterobacter Species                   48/50                         
50/50</p>
<p>Enterobacter cloacae                   24/24                         
24/24</p>
<p>Klebsiella Species                       53/54                         
54/54</p>
<p>Escherichia Coli                          63/63                       
  63/63</p>
<p>Serratia Species                         27/28                         
28/28</p>
<p>Proteus Mirabilis                        53/53                       
   53/53</p>
<p>Morganella Morganii                   10/10                          
10/10</p>
<p>Providencia Rettgeri                    2/2                          
   2/2</p>
<p>Proteus Vulgaris                         2/2                          
    2/2</p>
<p>Providencia Species                    1/1                             
1/1</p>
<p>Citrobacter Species                   10/10                         
10/10</p>
<p>Acinetobacter Calcoaceticus      10/11                          11/11</p>
<p>Stahylococcus Aureus             100/101                       101/101</p>
<p>Staphylococcus Epidermidis      51/51                           51/51</p>
<p>B-Hemolytic Streptococcus         4/4                              4/4</p>
<p>Enterococcus Species              52/53                          53/53</p>
<p>Corynebacterium Diphtheriae       2/2                               2/2</p>
<p>Clostridium Perfringens               0/2                              
2/2</p>
<p>Clostridium Perfringens               0/2                              
2/2</p>
<p><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> Albicans                    43/50                            
50/50</p>
<p><br></p>
<p>Silver sulfadiazine is not a carbonic anhydrase inhibitor and may be
useful in situations where such agents are contraindicated.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<p class="First"></p>
<p>Silver Sulfadiazine Cream is a topical antimicrobial drug indicated as
an adjunct for the prevention and treatment of <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> in patients with
second and third degree <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"></p>
<p>Silver Sulfadiazine Cream is contraindicated in patients who are
hypersensitive to silver sulfadiazine or any of the other ingredients in the
preparation.</p>
<p>Because sulfonamide therapy is known to increase the possibility of
<span class="product-label-link" type="condition" conceptid="4326231" conceptname="Kernicterus">kernicterus</span>, Silver Sulfadiazine Cream should not be used on pregnant women
approaching or at term, on premature infants, or on newborn infants during the
first 2 months of life.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"></p>
<p>There is a potential cross-sensitivity between silver sulfadiazine and
other sulfonamides.  If <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> attributable to treatment with
silver sulfadiazine occur, continuation of therapy must be weighed against the
potential hazards of the particular <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.  </p>
<p>Fungal proliferation in and below the <span class="product-label-link" type="condition" conceptid="4337954" conceptname="Eschar">eschar</span> may occur.  However, the
incidence of clinically reported fungal <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> is low.</p>
<p>The use of Silver Sulfadiazine Cream in some cases of
glucose-6-phosphate dehydrogenase-deficient individuals may be hazardous, as
<span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> may occur.<br></p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"></p>
<p>If hepatic and renal functions become impaired and elimination of the
drug decreases accumulation may occur and discontinuation of Silver
Sulfadiazine Cream should be weighed against the therapeutic benefit being
achieved.</p>
<p>In considering the use of topical proteolytic enzymes in conjunction
with Silver Sulfadiazine Cream, the possibility should be noted that silver may
inactivate such enzymes.</p>
<p><span class="Bold">Laboratory Tests: </span>In the treatment
of burn <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> involving extensive areas of the body, the serum sulfa
concentrations may approach adult therapeutic levels (8 to 12mg %).  Therefore,
in these patients it would be advisable to monitor serum sulfa concentrations. 
Renal function should be carefully monitored and the urine should be checked
for sulfa crystals.  <br></p>
<p>Absorption of the propylene glycol vehicle has been reported to affect
serum <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span>, which may affect the interpretation of laboratory tests.
<br></p>
<p><br></p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7"></a><p></p>
<h1>CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY</h1>
<p class="First"></p>
<p>Long-term dermal toxicity studies of 24 months duration in rats and 18
months in mice with concentrations of silver sulfadiazine three to ten times
the concentration in Silver Sulfadiazine Cream revealed no evidence of
carcinogenicity.</p>
<p><span class="Bold">Pregnancy: Pregnancy Category B.</span> A
reproductive study has been performed in rabbits at doses up to three to ten
times the concentration of silver sulfadiazine in Silver Sulfadiazine Cream and
has revealed no evidence of harm to the fetus due to silver sulfadiazine. 
There are, however, no adequate and well-controlled studies in pregnant women. 
Because animal reproduction studies are not always predictive of human
response, this drug should be used during pregnancy only if clearly justified,
especially in pregnant women approaching or at term.  (See <span class="Bold">CONTRAINDICATIONS</span>)</p>
<p><span class="Bold">Nursing Mother:</span> It is not known
whether Silver Sulfadiazine Cream is excreted in human milk.  However,
sulfonamides are known to be excreted in human milk and all sulfonamides
derivatives are known to increase the possibility of <span class="product-label-link" type="condition" conceptid="4326231" conceptname="Kernicterus">kernicterus</span>.  Because of
the potential for serious adverse reactions in nursing infants from
sulfonamides, a decision should be made whether to discontinue nursing or to
discontinue the drug, taking into account the importance of the drug to the
mother.  </p>
<p><span class="Bold">Pediatric Use: </span> Safety and
effectiveness in children have not been established.  (See <span class="Bold">CONTRAINDICATIONS</span>)</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"></p>
<p>Several cases of transient <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leucopenia</span> have been reported in patients
receiving silver sulfadiazine therapy.  <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leucopenia</span> associated with silver
sulfadiazine administration is primarily characterized by decreased neutrophil
count.  Maximal white blood cell <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> occurs within two to four days of
initiation of therapy.  Rebound to normal leukocyte levels follows onset within
two to three days.  Recovery is not influenced by continuation of silver
sulfadiazine therapy.  The incidence of <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leucopenia</span> in various reports averages
about 20%.  A higher incidence has been seen in patients treated concurrently
with cimetidine.</p>
<p>Other infrequently occurring events include <span class="product-label-link" type="condition" conceptid="4317266" conceptname="Skin necrosis">skin necrosis</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>
multiforme, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>, <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>, and interstitial
<span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>.  Reduction in bacterial growth after application of topical
antibacterial agents has been reported to permit spontaneous healing of deep
partial thickness <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span> by preventing conversion of the partial thickness to
full thickness by <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>.  However, reduction in bacterial colonization has
caused delayed separation, in some cases necessitating escharotomy in order to
prevent <span class="product-label-link" type="condition" conceptid="4208264" conceptname="Muscle contracture">contracture</span>.</p>
<p>Absorption of silver sulfadiazine varies depending upon the percent of
body surface area and the extent of the tissue damage.  Although few have been
reported, it is possible that any adverse reaction associated with sulfonamides
may occur.  Some of the reactions which have been associated with sulfonamides
are as follows: <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>,
<span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leucopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, dermatologic reactions,
<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>,
gastrointestinal reactions, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, hepatocellular <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, CNS reactions,
and toxic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<p class="First"></p>
<p>Prompt institution of appropriate regimens for care of the burned
patient is of prime importance and includes the control of <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.  The
burn <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> are then cleansed and debrided; Silver Sulfadiazine Cream is then
applied under sterile conditions.  The burn areas should be covered with Silver
Sulfadiazine Cream at all times.  The cream should be applied once to twice
daily to a thickness of approximately one sixteenth of an inch.  Whenever
necessary, the cream should be reapplied to any areas from which it has been
removed due to patient activity.  Administration may be accomplished in minimal
time because dressings are not required.  However, if individual patient
requirements make dressings necessary, they may be used.  Reapply immediately
after hydrotherapy.  Treatment with Silver Sulfadiazine Cream should be
continued until satisfactory healing has occurred or until the burn site is
ready for grafting.  The drug should not be withdrawn from the therapeutic
regimen while there remains the possibility of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> except if a
significant adverse reaction occurs.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<p><span>SSD™ </span>(1% Silver
Sulfadiazine) <span class="Bold">Cream</span>: white to off-white
cream.</p>
<p>50 gram jar                        NDC 43598-210-55 </p>
<p>400 gram jar                      NDC 43598-210-40 </p>
<p>25 gram tube                     NDC 43598-210-25 </p>
<p>50 gram tube                     NDC 43598-210-50 </p>
<p>85 gram tube                     NDC 43598-210-85 </p>
<p><span>SSD AF™ </span>(1% Silver
Sulfadiazine) <span class="Bold">Cream</span>: white to off-white
cream.</p>
<p>50 gram jar                         NDC 43598-211-55 </p>
<p>400 gram jar                       NDC 43598-211-40 </p>
<p>Store at controlled room temperature 15° - 30°C
(59° - 86°F)<br><br></p>
<p>SSD is a trademark of Dr. Reddy's Laboratories,
Inc.<br><br>Distributed by:<br>Dr. Reddy's Laboratories,
Inc.<br>Bridgewater, NJ 08807 USA</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-11"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First">
    DRUG: SSD Cream  </p>
<p><br></p>
<p>GENERIC: Silver Sulfadiazine</p>
<p><br></p>
<p>DOSAGE: CREAM</p>
<p><br></p>
<p>ADMINSTRATION: TOPICAL</p>
<p><br></p>
<p>NDC: 52125-688-16</p>
<p><br></p>
<p>ACTIVE INGREDIENT(S):</p>
<ul><li>Silver Sulfadiazine 10g in 1000g</li></ul>
<p><br></p>
<p>INACTIVE INGREDIENT(S):</p>
<ul>
<li>ISOPROPYL MYRISTATE</li>
<li>METHYLPARABEN</li>
<li>PROPYLENE GLYCOL</li>
<li>SORBITAN MONOOLEATE</li>
<li>POLYOXYL 40 STEARATE</li>
<li>CETYL ALCOHOL</li>
<li>PETROLATUM</li>
<li>STEARYL ALCOHOL</li>
<li>WATER</li>
</ul>
<p><br></p>
<p>PACKAGING: 50 g in 1 TUBE</p>
<p><br></p>
<p><br></p>
<p><br></p>
<p><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cecc0b75-fccf-418d-923a-2a5869c1d043&amp;name=MM2.jpg"></p>
<p><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cecc0b75-fccf-418d-923a-2a5869c1d043&amp;name=MM3.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SSD CREAM  		
					</strong><br><span class="contentTableReg">silver sulfadiazine cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52125-688(NDC:43598-210)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Silver Sulfadiazine</strong> (SULFADIAZINE) </td>
<td class="formItem">Silver Sulfadiazine</td>
<td class="formItem">10 g  in 1000 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ISOPROPYL MYRISTATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITAN MONOOLEATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYOXYL 40 STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CETYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PETROLATUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52125-688-16</td>
<td class="formItem">50 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018578</td>
<td class="formItem">12/02/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 12/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7a1806ce-8958-47e9-bdec-ba619db92c2c</div>
<div>Set id: cecc0b75-fccf-418d-923a-2a5869c1d043</div>
<div>Version: 1</div>
<div>Effective Time: 20131202</div>
</div>
</div> <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
